These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34802948)

  • 21. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.
    Marchoudi N; Amrani Hassani Joutei H; Jouali F; Fekkak J; Rhaissi H
    Pathol Biol (Paris); 2013 Dec; 61(6):273-6. PubMed ID: 23849768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.
    Akhoundova D; Pietge H; Hussung S; Kiessling M; Britschgi C; Zoche M; Rechsteiner M; Weber A; Fritsch RM
    JCO Precis Oncol; 2021 Nov; 5():1082-1087. PubMed ID: 34994629
    [No Abstract]   [Full Text] [Related]  

  • 23. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reply to the Letter by S. Sorscher Regarding "Implications of BRAF Mutations in dMMR Colorectal Cancers".
    Cohen R; André T
    Curr Treat Options Oncol; 2017 Sep; 18(10):63. PubMed ID: 28921484
    [No Abstract]   [Full Text] [Related]  

  • 27. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
    Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].
    Robešová B; Bajerová M; Vašíková A; Ostřížková L; Hausnerová J; Kyclová J; Pospíšilová S; Mayer J; Dvořáková D
    Klin Onkol; 2013; 26(1):25-30. PubMed ID: 23528169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-Raf mutation: a key player in molecular biology of cancer.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Exp Mol Pathol; 2013 Dec; 95(3):336-42. PubMed ID: 24161954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Class 1, 2, and 3
    Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
    Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF mutation: Current and future clinical pathological applications in colorectal carcinoma.
    Ng JY; Lu CT; Lam AK
    Histol Histopathol; 2019 May; 34(5):469-477. PubMed ID: 30592501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
    Sclafani F; Gullo G; Sheahan K; Crown J
    Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging predictors of BRAF mutation in colorectal cancer.
    Eurboonyanun K; Lahoud RM; Kordbacheh H; Pourvaziri A; Promsorn J; Chadbunchachai P; O'Shea A; Atre ID; Harisinghani M
    Abdom Radiol (NY); 2020 Aug; 45(8):2336-2344. PubMed ID: 32193591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double
    Deshwar A; Margonis GA; Andreatos N; Barbon C; Wang J; Buettner S; Wagner D; Sasaki K; Beer A; Løes IM; Pikoulis E; Damaskos C; Garmpis N; Kamphues K; He J; Kaczirek K; Poultsides G; Lønning PE; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    Anticancer Res; 2018 May; 38(5):2891-2895. PubMed ID: 29715113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer].
    Kawakami H; Ogata S
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):787-795. PubMed ID: 34139726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.
    Ličar A; Cerkovnik P; Novaković S
    Med Oncol; 2011 Dec; 28(4):1048-53. PubMed ID: 20645028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.
    Rosty C; Williamson EJ; Clendenning M; Walters RJ; Walsh MD; Win AK; Jenkins MA; Hopper JL; Winship I; Southey MC; Giles GG; English DR; Buchanan DD
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25114271
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.